Jardiance needs approval first for 23% of Medicare Advantage drug plan members, up from none.

In 2027, Jardiance needs approval first for 23% of Medicare Advantage drug plan members. In 2026, for none.

The 2027 Medicare drug lists are out, and we loaded every plan's list into Vlada.

It is mostly one insurer. On Humana's 2027 lists, your doctor must get approval before you can fill Jardiance, in plans covering 5.6 million members. Humana adds the same step for Farxiga. A few regional plans, like Priority Health in Michigan and UPMC in Pennsylvania, add it too.

These are two of the first drugs Medicare negotiated. Jardiance's 2026 negotiated price is $197 for a month's supply, against a $573 list price. Farxiga's is $178.50.

Generic versions of Farxiga (dapagliflozin) need no approval at Humana, on the same tier as Jardiance.

So where you live matters. In Louisiana, 45% of these members need approval first. In New York, 3%.

Jardiance and dapagliflozin are in the same drug class, but they are not the same pill. An approval step is not a denial, and people already on it can usually get a one-time temporary supply early in the year while the doctor asks. If you or a parent take Jardiance, ask the doctor before December 7 whether 2027 means a request or a switch.

Medicare set the price. Your plan sets the rules.